Company Scopus BioPharma Inc.

Equities

SCPS

US8091711015

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Market Closed - OTC Markets Other stock markets 01:19:55 10/05/2024 am IST			5-day change	1st Jan Change
0.0011 ^USD	-47.62%		0.00%	-97.45%

2023	Scopus BioPharma Inc. Presents DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma	CI
2023	Scopus BioPharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs. The Companyâs Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.

Number of employees: 13

Managers	Title	Age	Since
Robert J. Gibson BRD	Director/Board Member	44	18/17/18

Members of the board	Title	Age	Since
David Buckel BRD	Director/Board Member	62	16/20/16
David Weild BRD	Director/Board Member	67	16/20/16
Raf Hofstein BRD	Director/Board Member	74	16/20/16
Robert J. Gibson BRD	Director/Board Member	44	18/17/18
Ira Greenspan BRD	Director/Board Member	65	18/17/18
Joshua Lamstein CHM	Chairman	55	01/17/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	42,084,264	34,219,550 ( 81.31 %)	0	81.31 %

Name	Equities	%	Valuation
Morris Laster 11.71 %	4,926,000	11.71 %	4 926 $
Armistice Capital LLC 4.990 %	2,100,000	4.990 %	2 100 $
Ira Greenspan 3.613 %	1,520,424	3.613 %	1 520 $
Joshua Lamstein 3.493 %	1,469,997	3.493 %	1 470 $
Chen Laster 0.8554 %	360,000	0.8554 %	360 $
Gabriella Laster 0.8554 %	360,000	0.8554 %	360 $
Sara Laster 0.8554 %	360,000	0.8554 %	360 $
Robert J. Gibson 0.5046 %	212,352	0.5046 %	212 $
David Buckel 0.0141 %	5,941	0.0141 %	6 $
FSA Wealth Management LLC 0.000238 %	100	0.000238 %	0 $

Scopus Biopharma, Inc.

420 Lexington Avenue Suite 300

10170, New York

http://www.scopusbiopharma.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SCOPUS BIOPHARMA INC.	-97.45%	46.29K
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs